Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Left-to-right inter-atrial blood flow" refers to an **abnormal pattern of blood movement across the atria**, typically through a defect such as an atrial septal defect (ASD), where oxygenated blood from the left atrium flows into the right atrium. This is not a molecule or receptor but rather a **physiological phenomenon or hemodynamic consequence of structural cardiac defects**, most commonly congenital in origin. The main causes include ASD, ventricular septal defect (VSD), patent ductus arteriosus (PDA), and other septal abnormalities that allow communication between systemic and pulmonary circulations[1][6]. In these conditions: - The increased compliance of the right ventricle compared to the left favors this abnormal flow direction in most patients with ASD. - Chronic excessive pulmonary blood flow can lead to vascular remodeling, irreversible pulmonary hypertension, right heart enlargement/failure, and eventually reversal of shunt direction if untreated (Eisenmenger syndrome)[2][4]. Therapeutically, recent innovations include percutaneously implanted devices like the V-Wave device that intentionally create controlled unidirectional interatrial shunts in select patients with refractory heart failure to decompress elevated left atrial pressures—this is not drug-based therapy but rather mechanical intervention[3]. Because "left-to-right inter-atrial blood flow" describes a pathophysiological process—not a discrete molecular target—it is **not considered a therapeutic target like receptors or enzymes**, nor does it have canonical molecular identifiers. It should be classified under "Other" for molecular classification. If you require structured data on actual molecules/receptors involved in regulating cardiac development or function related to these processes—such as ion channels or signaling proteins—please specify further.
Not applicable for drugs; for devices, mechanical decompression of the left atrium via creation of a unidirectional interatrial shunt[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Left-to-right inter-atrial blood flow.